Menu
Recruiting NCT06108414

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Phase IV Interventional Atrial Fibrillation Anticoagulant Adverse Reaction Stroke Major Adverse Cardiac Events

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: low-dose rivaroxaban, Standard-dose rivaroxaban.
Who it may be relevant to
Registry conditions: Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke, Major Adverse Cardiac Events. Basic parameters: from 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Efficacy and Safety of Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Overview

To evaluate the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation.

Interventions

  • Drug low-dose rivaroxaban
    Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
  • Drug Standard-dose rivaroxaban
    Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)

Primary outcome measures

  • Major adverse cardiovascular and cerebrovascular events(MACCE) [Time frame: Through study completion, an estimated average of 2 years]
Secondary outcome measures (3)
  • Bleeding events [Time frame: Through study completion, an estimated average of 2 years]
  • Net clinical benefit [Time frame: Through study completion, an estimated average of 2 years]
  • Components of all primary and secondary outcome measures [Time frame: Through study completion, an estimated average of 2 years]

Eligibility criteria

Inclusion criteria

  • Age ≥70 years
  • Patients with atrial fibrillation (atrial fibrillation rhythm of at least 30 seconds duration recorded by ECG or Holter within 1 year)
  • CHA2DS2-VASc score ≥2 in men and ≥3 in women
  • Able to cooperate in signing ICFs

Exclusion criteria：

  • Moderate-to-severe mitral stenosis, or prior mechanical valve replacement surgery, or unresected atrial myxoma, or known left ventricular thrombus
  • Prior biological valve replacement or valve repair surgery within 6 months
  • Left ventricular assist device implantation status
  • Severe stroke event within 3 months or any stroke within 14 days Major stroke events were defined as those with a Modified Rankin Scale score of 3-5.

Score 3: moderately disabled, requiring some assistance but walking without assistance; Score 4: severe disability, unable to walk independently, unable to meet their own needs without the help of others; Score 5: severe disability, bedridden, incontinent, requiring ongoing care and attention

  • Transient ischemic attack (TIA) occurred within 3 days
  • Transient atrial fibrillation due to reversible triggers (e.g., after cardiac surgery, pulmonary embolism, untreated hyperthyroidism)
  • Prior or planning to undergo atrial fibrillation catheter ablation, drug cardioversion, electroconversion, or major surgery in 3 months; Prior catheter or surgical ablation > 3 months without atrial fibrillation electrocardiogram records
  • Prior or planning to undergo left atrial appendage occlusion
  • Active infective endocarditis
  • High or increasing risk for bleeding i. Traumatic surgery that has been completed within the last 3 months or is planned within the next 3 months ii. Previous severe intracranial, intraocular, spinal cord, retroperitoneal, or nontraumatic intra-articular hemorrhage.

iii. Gastrointestinal bleeding within the past year iv. Symptomatic or gastroscopic peptic ulcer within the last month v. Hemorrhagic constitution or coagulopathy vi. Difficult-controlled hypertension (180mm Hg systolic and/or 100 mm Hg diastolic)

  • Severe renal impairment (estimated creatinine clearance ≤ 15 mL/min)
  • Active liver disease

Including but not limited to:

i. Persistent ALT, AST > 2×ULN; ii. TBil > 1.5×ULN; iii. Known active hepatitis A, B or C; iv. Cirrhosis

  • Hemoglobin level <100g/L or thrombocytopenia count <100 × 10\^9/L
  • Having conditions warrant standard-dose or low-dose anticoagulation treatment (non-AF, such as VTE)
  • Having conditions warrant warfarin anticoagulation treatment
  • Daily dose of aspirin >100mg
  • Having received dual antiplatelet therapy or intravenous antiplatelet drugs within 5 days (note: P2Y12 receptor antagonist alone or ≤ 100mg aspirin alone can be enrolled)
  • Having received fibrinolysis treatment in 10 days or planning to use fibrinolytic drugs
  • Having conditions warrant the following medications: CYP3A4 and P-gp inhibitors (itraconazole, ketoconazole, voriconazole, posaconazole, clarithromycin, erythromycin, fluconazole, ritonavir, dronedarone, etc.), selective serotonin reuptake inhibitors (SSRI)/serotonin norepinephrine reuptake inhibitors (SNRI) drugs (fluoxetine, paroxelin, etc.) CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's wort, etc.), long-term use of NSAIDs
  • Having allergic or adverse reactions to any excipients (including but not limited to lactose, starch, etc.) in rivaroxaban tablets, including but not limited to hereditary lactose or galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, etc.
  • Having diagnosed with malignant tumors within 6 months, or receiving radiotherapy/chemotherapy, with an expected lifespan of no more than 3 years
  • Antiphospholipid syndrome
  • Having been enrolled in another interventional clinical trial within the past 30 days or at the same time
  • Mental disorders, communication barriers, cognitive impairment, or other serious illnesses that may affect the participation in this study
  • Known poor adherence to study follow-up or taking study drugs
  • Other conditions deemed by the investigator to be inappropriate for enrollment

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

China · 1 center
  • National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Car — Beijing

Publications

  • Han J, Qi W, Yuan S, Liu H, Wang Y, Zhang H, Liu J, Zhao Y, Zhang Y, Zheng L, Yao Y, Zheng Z. Efficacy and safety of low-dose rivaroxaban in elderly patients with atrial fibrillation for oral anticoagulation therapy: Rationale, design, and study protocol for a multicenter randomized controlled trial (SAFE-AF). Am Heart J. 2025 Dec;290:268-277. doi: 10.1016/j.ahj.2025.07.011. Epub 2025 Jul 15. PMID 40675206

Identifiers

NCT: NCT06108414 · NCRC2022002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗